BioCentury
ARTICLE | Emerging Company Profile

Vantia: New irons in the fire

November 17, 2008 8:00 AM UTC

Vantia Therapeutics Ltd. spun out of Ferring Pharmaceuticals A/S with a portfolio of small molecules that includes a pair of vasopressin receptor modulators with disease-modifying potential. The company believes its lead program, a vasopressin 2 agonist in Phase II testing to treat nocturia, a urinary disorder, will complement drugs marketed for benign prostatic hyperplasia.

A second compound, VA111913, could replace hormone therapies for dysmenorrhea, a condition characterized by severe uterine pain during menstruation...